Show Nav →
Please include the following statement when referencing the CPTAC Assay Portal
We would like to acknowledge the National Cancer Institute’s Clinical Proteomic Tumor Analysis Consortium (CPTAC) Assay Portal (assays.cancer.gov) for developing assays and establishing criteria for the assays described in this publication.

VCAN

Previous Assay Next Assay
Available Assays

Overview Data source: UniProt

Official Gene Symbol Other Aliases
VCAN CSPG2
Sequence Length (AA) Molecular Weight (Da)
3396 372820
Protein Name
Versican core protein
Sources
UniProt
PhosphoSitePlus ®
GeneCards 		Human Protein Atlas

Protein Sequence hover to view complete sequence

10 20 30 40 50
MFINIKSILW MCSTLIVTHA LHKVKVGKSP PVRGSLSGKV SLPCHFSTMP
60 70 80 90 100
TLPPSYNTSE FLRIKWSKIE VDKNGKDLKE TTVLVAQNGN IKIGQDYKGR
110 120 130 140 150
VSVPTHPEAV GDASLTVVKL LASDAGLYRC DVMYGIEDTQ DTVSLTVDGV
160 170 180 190 200
VFHYRAATSR YTLNFEAAQK ACLDVGAVIA TPEQLFAAYE DGFEQCDAGW
210 220 230 240 250
LADQTVRYPI RAPRVGCYGD KMGKAGVRTY GFRSPQETYD VYCYVDHLDG
260 270 280 290 300
DVFHLTVPSK FTFEEAAKEC ENQDARLATV GELQAAWRNG FDQCDYGWLS
310 320 330 340 350
DASVRHPVTV ARAQCGGGLL GVRTLYRFEN QTGFPPPDSR FDAYCFKPKE
360 370 380 390 400
ATTIDLSILA ETASPSLSKE PQMVSDRTTP IIPLVDELPV IPTEFPPVGN
410 420 430 440 450
IVSFEQKATV QPQAITDSLA TKLPTPTGST KKPWDMDDYS PSASGPLGKL
460 470 480 490 500
DISEIKEEVL QSTTGVSHYA TDSWDGVVED KQTQESVTQI EQIEVGPLVT
510 520 530 540 550
SMEILKHIPS KEFPVTETPL VTARMILESK TEKKMVSTVS ELVTTGHYGF
560 570 580 590 600
TLGEEDDEDR TLTVGSDEST LIFDQIPEVI TVSKTSEDTI HTHLEDLESV
610 620 630 640 650
SASTTVSPLI MPDNNGSSMD DWEERQTSGR ITEEFLGKYL STTPFPSQHR
660 670 680 690 700
TEIELFPYSG DKILVEGIST VIYPSLQTEM THRRERTETL IPEMRTDTYT
710 720 730 740 750
DEIQEEITKS PFMGKTEEEV FSGMKLSTSL SEPIHVTESS VEMTKSFDFP
760 770 780 790 800
TLITKLSAEP TEVRDMEEDF TATPGTTKYD ENITTVLLAH GTLSVEAATV
810 820 830 840 850
SKWSWDEDNT TSKPLESTEP SASSKLPPAL LTTVGMNGKD KDIPSFTEDG
860 870 880 890 900
ADEFTLIPDS TQKQLEEVTD EDIAAHGKFT IRFQPTTSTG IAEKSTLRDS
910 920 930 940 950
TTEEKVPPIT STEGQVYATM EGSALGEVED VDLSKPVSTV PQFAHTSEVE
960 970 980 990 1000
GLAFVSYSST QEPTTYVDSS HTIPLSVIPK TDWGVLVPSV PSEDEVLGEP
1010 1020 1030 1040 1050
SQDILVIDQT RLEATISPET MRTTKITEGT TQEEFPWKEQ TAEKPVPALS
1060 1070 1080 1090 1100
STAWTPKEAV TPLDEQEGDG SAYTVSEDEL LTGSERVPVL ETTPVGKIDH
1110 1120 1130 1140 1150
SVSYPPGAVT EHKVKTDEVV TLTPRIGPKV SLSPGPEQKY ETEGSSTTGF
1160 1170 1180 1190 1200
TSSLSPFSTH ITQLMEETTT EKTSLEDIDL GSGLFEKPKA TELIEFSTIK
1210 1220 1230 1240 1250
VTVPSDITTA FSSVDRLHTT SAFKPSSAIT KKPPLIDREP GEETTSDMVI
1260 1270 1280 1290 1300
IGESTSHVPP TTLEDIVAKE TETDIDREYF TTSSPPATQP TRPPTVEDKE
1310 1320 1330 1340 1350
AFGPQALSTP QPPASTKFHP DINVYIIEVR ENKTGRMSDL SVIGHPIDSE
1360 1370 1380 1390 1400
SKEDEPCSEE TDPVHDLMAE ILPEFPDIIE IDLYHSEENE EEEEECANAT
1410 1420 1430 1440 1450
DVTTTPSVQY INGKHLVTTV PKDPEAAEAR RGQFESVAPS QNFSDSSESD
1460 1470 1480 1490 1500
THPFVIAKTE LSTAVQPNES TETTESLEVT WKPETYPETS EHFSGGEPDV
1510 1520 1530 1540 1550
FPTVPFHEEF ESGTAKKGAE SVTERDTEVG HQAHEHTEPV SLFPEESSGE
1560 1570 1580 1590 1600
IAIDQESQKI AFARATEVTF GEEVEKSTSV TYTPTIVPSS ASAYVSEEEA
1610 1620 1630 1640 1650
VTLIGNPWPD DLLSTKESWV EATPRQVVEL SGSSSIPITE GSGEAEEDED
1660 1670 1680 1690 1700
TMFTMVTDLS QRNTTDTLIT LDTSRIITES FFEVPATTIY PVSEQPSAKV
1710 1720 1730 1740 1750
VPTKFVSETD TSEWISSTTV EEKKRKEEEG TTGTASTFEV YSSTQRSDQL
1760 1770 1780 1790 1800
ILPFELESPN VATSSDSGTR KSFMSLTTPT QSEREMTDST PVFTETNTLE
1810 1820 1830 1840 1850
NLGAQTTEHS SIHQPGVQEG LTTLPRSPAS VFMEQGSGEA AADPETTTVS
1860 1870 1880 1890 1900
SFSLNVEYAI QAEKEVAGTL SPHVETTFST EPTGLVLSTV MDRVVAENIT
1910 1920 1930 1940 1950
QTSREIVISE RLGEPNYGAE IRGFSTGFPL EEDFSGDFRE YSTVSHPIAK
1960 1970 1980 1990 2000
EETVMMEGSG DAAFRDTQTS PSTVPTSVHI SHISDSEGPS STMVSTSAFP
2010 2020 2030 2040 2050
WEEFTSSAEG SGEQLVTVSS SVVPVLPSAV QKFSGTASSI IDEGLGEVGT
2060 2070 2080 2090 2100
VNEIDRRSTI LPTAEVEGTK APVEKEEVKV SGTVSTNFPQ TIEPAKLWSR
2110 2120 2130 2140 2150
QEVNPVRQEI ESETTSEEQI QEEKSFESPQ NSPATEQTIF DSQTFTETEL
2160 2170 2180 2190 2200
KTTDYSVLTT KKTYSDDKEM KEEDTSLVNM STPDPDANGL ESYTTLPEAT
2210 2220 2230 2240 2250
EKSHFFLATA LVTESIPAEH VVTDSPIKKE ESTKHFPKGM RPTIQESDTE
2260 2270 2280 2290 2300
LLFSGLGSGE EVLPTLPTES VNFTEVEQIN NTLYPHTSQV ESTSSDKIED
2310 2320 2330 2340 2350
FNRMENVAKE VGPLVSQTDI FEGSGSVTST TLIEILSDTG AEGPTVAPLP
2360 2370 2380 2390 2400
FSTDIGHPQN QTVRWAEEIQ TSRPQTITEQ DSNKNSSTAE INETTTSSTD
2410 2420 2430 2440 2450
FLARAYGFEM AKEFVTSAPK PSDLYYEPSG EGSGEVDIVD SFHTSATTQA
2460 2470 2480 2490 2500
TRQESSTTFV SDGSLEKHPE VPSAKAVTAD GFPTVSVMLP LHSEQNKSSP
2510 2520 2530 2540 2550
DPTSTLSNTV SYERSTDGSF QDRFREFEDS TLKPNRKKPT ENIIIDLDKE
2560 2570 2580 2590 2600
DKDLILTITE STILEILPEL TSDKNTIIDI DHTKPVYEDI LGMQTDIDTE
2610 2620 2630 2640 2650
VPSEPHDSND ESNDDSTQVQ EIYEAAVNLS LTEETFEGSA DVLASYTQAT
2660 2670 2680 2690 2700
HDESMTYEDR SQLDHMGFHF TTGIPAPSTE TELDVLLPTA TSLPIPRKSA
2710 2720 2730 2740 2750
TVIPEIEGIK AEAKALDDMF ESSTLSDGQA IADQSEIIPT LGQFERTQEE
2760 2770 2780 2790 2800
YEDKKHAGPS FQPEFSSGAE EALVDHTPYL SIATTHLMDQ SVTEVPDVME
2810 2820 2830 2840 2850
GSNPPYYTDT TLAVSTFAKL SSQTPSSPLT IYSGSEASGH TEIPQPSALP
2860 2870 2880 2890 2900
GIDVGSSVMS PQDSFKEIHV NIEATFKPSS EEYLHITEPP SLSPDTKLEP
2910 2920 2930 2940 2950
SEDDGKPELL EEMEASPTEL IAVEGTEILQ DFQNKTDGQV SGEAIKMFPT
2960 2970 2980 2990 3000
IKTPEAGTVI TTADEIELEG ATQWPHSTSA SATYGVEAGV VPWLSPQTSE
3010 3020 3030 3040 3050
RPTLSSSPEI NPETQAALIR GQDSTIAASE QQVAARILDS NDQATVNPVE
3060 3070 3080 3090 3100
FNTEVATPPF SLLETSNETD FLIGINEESV EGTAIYLPGP DRCKMNPCLN
3110 3120 3130 3140 3150
GGTCYPTETS YVCTCVPGYS GDQCELDFDE CHSNPCRNGA TCVDGFNTFR
3160 3170 3180 3190 3200
CLCLPSYVGA LCEQDTETCD YGWHKFQGQC YKYFAHRRTW DAAERECRLQ
3210 3220 3230 3240 3250
GAHLTSILSH EEQMFVNRVG HDYQWIGLND KMFEHDFRWT DGSTLQYENW
3260 3270 3280 3290 3300
RPNQPDSFFS AGEDCVVIIW HENGQWNDVP CNYHLTYTCK KGTVACGQPP
3310 3320 3330 3340 3350
VVENAKTFGK MKPRYEINSL IRYHCKDGFI QRHLPTIRCL GNGRWAIPKI
3360 3370 3380 3390 3396
TCMNPSAYQR TYSMKYFKNS SSAKDNSINT SKHDHRWSRR WQESRR

Data source: UniProt

Protein Map Collapse protein map

Position of Targeted Peptide Analytes Relative to SNPs, Isoforms, and PTMs

Uniprot Database Entry PhosphoSitePlus ®

Click a point on a node
to view detailed assay information below
All other points link out to UniProt


Phosphorylation Acetylation Ubiquitylation Other

loading

Loader

Assay Details for CPTAC-5841 Collapse assay details

Data source: Panorama

Official Gene Symbol
VCAN
Peptide Sequence
VSVPTHPEAVGDASLTVVK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
6
Peptide Start
101
Peptide End
119
CPTAC ID
CPTAC-5841
Peptide Molecular Mass
1,905.0207
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
Frozen breast cancer tumor tissue lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTRAP 6500
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent nanoLC 425
Column Packing
3 µm ChromXP C18EP, 120 Å
Column Dimensions
150 x 0.3 mm
Flow Rate
10.0 µL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y16 (2+) 12.6 6 4.2 12.5 11.5 5 17.7 13 6.5 15 17 15
y17 (2+) 12.9 7.1 4.9 14.8 11.2 6.7 19.6 13.3 8.3 15 17 15
y18 (2+) 17.8 5 5.9 16.9 8.4 7.8 24.5 9.8 9.8 15 17 15
y6 (1+) 14.9 7.1 8.7 17.1 9 9.5 22.7 11.5 12.9 15 17 15
y9 (1+) 16.4 7.2 8.4 20.6 9.8 10.6 26.3 12.2 13.5 15 17 15
sum 12.7 5.2 3.7 13 10.4 5.4 18.2 11.6 6.5 15 17 15

Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments

Assay Details for CPTAC-5866 Collapse assay details

Data source: Panorama

Official Gene Symbol
VCAN
Peptide Sequence
VSVPTHPEAVGDASLTVVK
Modification Type
unmodified
Protein - Site of Modification
N/A
Peptide - Site of Modification
6
Peptide Start
101
Peptide End
119
CPTAC ID
CPTAC-5866
Peptide Molecular Mass
1,905.0207
Species
Homo sapiens (Human)
Assay Type
Enrichment MRM
Enrichment Method
peptide immunoaffinity
Matrix
FFPE breast cancer tumor tissue lysate pool
Submitting Laboratory
Fred Hutchinson Cancer Research Center
Submitting Lab PI
Amanda Paulovich

Publication

View Details (opens in a new window)

Quantification of Human Epidermal Growth Factor Receptor 2 by Immunopeptide Enrichment and Targeted Mass Spectrometry in Formalin-Fixed Paraffin-Embedded and Frozen Breast Cancer Tissues. Kennedy JJ, Whiteaker JR, Kennedy LC, Bosch DE, Lerch ML, Schoenherr RM, Zhao L, Lin C, Chowdhury S, Kilgore MR, Allison KH, Wang P, Hoofnagle AN, Baird GS, Paulovich AG. Clin Chem. 2021 Jun 17:hvab047. doi: 10.1093/clinchem/hvab047. Online ahead of print. PMID: 34136904

Assay Parameters Collapse assay parameters

Data source: Panorama

Instrument
QTRAP 6500
Internal Standard
peptide
Peptide Standard Purity
>95%
Peptide Standard Label Type
13C and 15N at C-terminus K
LC
Eksigent nanoLC 425
Column Packing
3 µm ChromXP C18EP, 120 Å
Column Dimensions
150 x 0.3 mm
Flow Rate
10.0 µL/min

Chromatograms

Data source: Panorama

view larger image
view larger image
view larger image

Response Curves

Data source: Panorama

view larger image
view larger image
view larger image

Retrieving Data

Loader

Repeatability

Data source: Panorama

view larger image
  Average intra-assay CV
(within day CV)		 Average inter-assay CV
(between day CV)		 Total CV
equation		 n=
Fragment ion / Transition Low Med High Low Med High Low Med High Low Med High
y18 (2+) 9.4 7.4 8.4 14.8 7.4 6.4 17.5 10.5 10.6 12 12 12
y17 (2+) 9.1 7.1 7.5 14.4 10.4 7.7 17 12.6 10.7 12 12 12
y16 (2+) 11.2 9 4.8 15.8 9.8 6.8 19.4 13.3 8.3 12 12 12
y9 (1+) 12.4 8.6 10.7 21 8.7 7.2 24.4 12.2 12.9 12 12 12
y6 (1+) 16.3 8.5 9.9 21.3 8.6 7.5 26.8 12.1 12.4 12 12 12
sum 9.8 6.6 5.5 14.8 8 6.3 17.8 10.4 8.4 12 12 12

Additional Resources and Comments

Resources
Download SOPs
View Peptide in Panorama
View Protein in Panorama
Comments